This study was aimed at analyzing the efficacy and safety of an injectable form of CHA in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial.

This study demonstrates an efficient two-photon fluorescent tool for real-time assessment of mitochondrial O2•− and a clear link between reducing intracellular ROS levels by CHA treatments and regulating metabolism, as well as undeniably helpful insights for the development of new anticancer strategies.

CHA is a phenylpropyl substance synthesized through the shikimic acid pathway. In addition to its anti-tumor, anti-inflammatory, and antioxidant abilities, CHA also has immunomodulatory effects. The aim of the present study is to investigate the therapeutic effects of CHA on the skin damage and arthritis caused by systemic lupus erythematosus (SLE) in an MRL/lpr mouse model. In the SLE model, female MRL/lpr mice at the age of 10 weeks old were treated with CHA daily or cyclophosphamide (CTX) weekly via intraperitoneal injection for three months. After treatment, CHA can significantly alleviate the skin and mucous membrane damage caused by SLE and has a certain improvement effect on arthritis. CHA could inhibit dsDNA expression to a certain extent but has no obvious regulation on ANA concentration. The ELISA and BioMAP results indicated that CHA might play an anti-inflammatory role by down-regulating the interleukin (IL)-17 level. In conclusion, our study demonstrates that CHA can alleviate multiorgan damage in MRL/lpr mice by reducing IL-17.

our study, for the first time, demonstrate that CHA has protective effects during skin photoaging, especially triggered by UVA-irradiation, and provide rationales for further investigation of CHA being used to prevent or treat skin aging.

These findings indicate that CHA-SME have great potential to enhance the immunotherapeutic efficacy of CHA by activating antitumor immune responses.

This study aims to investigate the effect and mechanism of Notch1 in the process of CHA suppressing esophageal squamous cell carcinoma (ESCC).